Brokers Offer Predictions for Teladoc Health FY2024 Earnings

Teladoc Health, Inc. (NYSE:TDOC) – Equities researchers at William Blair reduced their FY2024 EPS estimates for Teladoc Health in a research report issued on Wednesday, October 30th. William Blair analyst R. Daniels now forecasts that the health services provider will earn ($1.11) per share for the year, down from their previous forecast of ($0.93). The consensus estimate for Teladoc Health’s current full-year earnings is ($1.18) per share. William Blair also issued estimates for Teladoc Health’s Q4 2024 earnings at ($0.15) EPS, Q1 2025 earnings at ($0.27) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.08) EPS and FY2025 earnings at ($0.71) EPS.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings results on Wednesday, October 30th. The health services provider reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.10. The business had revenue of $640.51 million for the quarter, compared to the consensus estimate of $630.50 million. Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 9.40%.

Several other equities analysts also recently commented on TDOC. Piper Sandler cut their target price on Teladoc Health from $25.00 to $10.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Needham & Company LLC reissued a “hold” rating on shares of Teladoc Health in a report on Thursday, August 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $10.00 target price on shares of Teladoc Health in a report on Tuesday, August 20th. Canaccord Genuity Group dropped their target price on shares of Teladoc Health from $25.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. Finally, Evercore ISI boosted their price target on shares of Teladoc Health from $8.00 to $9.00 and gave the company an “in-line” rating in a research report on Tuesday, October 8th. Fourteen research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $11.97.

Teladoc Health Stock Performance

NYSE:TDOC opened at $9.21 on Monday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.62 and a current ratio of 1.66. The firm’s 50-day moving average is $8.48 and its 200-day moving average is $9.66. Teladoc Health has a 52-week low of $6.76 and a 52-week high of $22.54. The company has a market cap of $1.58 billion, a price-to-earnings ratio of -1.60 and a beta of 0.90.

Insider Activity

In other news, Director Thomas Mckinley acquired 4,000 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was purchased at an average cost of $7.69 per share, for a total transaction of $30,760.00. Following the completion of the transaction, the director now directly owns 39,077 shares in the company, valued at $300,502.13. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Teladoc Health news, Director Thomas Mckinley bought 4,000 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was bought at an average price of $7.69 per share, for a total transaction of $30,760.00. Following the transaction, the director now owns 39,077 shares of the company’s stock, valued at approximately $300,502.13. The trade was a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CMO Stephany Verstraete sold 15,000 shares of the stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $7.60, for a total value of $114,000.00. Following the completion of the transaction, the chief marketing officer now directly owns 45,158 shares in the company, valued at approximately $343,200.80. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 35,051 shares of company stock valued at $257,565. Company insiders own 0.95% of the company’s stock.

Hedge Funds Weigh In On Teladoc Health

Several institutional investors have recently modified their holdings of TDOC. Signaturefd LLC raised its stake in Teladoc Health by 148.7% during the 2nd quarter. Signaturefd LLC now owns 2,868 shares of the health services provider’s stock worth $28,000 after buying an additional 1,715 shares during the period. International Assets Investment Management LLC acquired a new stake in shares of Teladoc Health during the second quarter worth about $29,000. Blue Trust Inc. lifted its holdings in shares of Teladoc Health by 84.5% during the 3rd quarter. Blue Trust Inc. now owns 4,048 shares of the health services provider’s stock valued at $40,000 after purchasing an additional 1,854 shares in the last quarter. Doheny Asset Management CA acquired a new position in shares of Teladoc Health in the 2nd quarter valued at approximately $46,000. Finally, SageView Advisory Group LLC acquired a new position in shares of Teladoc Health in the 1st quarter valued at approximately $48,000. 76.82% of the stock is currently owned by institutional investors and hedge funds.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.